Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Iron vs Ferrous Ascorbate for IDA in Children
NCT05957328Phase 3Unknown
- Sponsor
- AIIMS New Delhi
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ferric pyrophosphate liposomal in iron deficiency anemia (IDA) (2 arms), sponsored by AIIMS New Delhi. Primary endpoint: Change in Hemoglobin concentration at 12 weeks. Status: unknown.
02
Drugs
ferric pyrophosphate liposomal
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05957328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957328.